Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VTB launched a pilot to reach out to the mass client segment

7/27/23 VTBR

Renaissance Insurance reported for 6 months of 2023 by RAS

7/27/23 RENI

RusHydro reported for 6 months of 2023 by RAS

7/27/23 HYDR

Mastercard reported for 6 months of 2023

7/27/23 MA

MTS enters the market of digital financial assets

7/27/23 MTSS

AbbVie reported for 6 months of 2023

7/27/23 ABBV

Comcast reported for 6 months of 2023

7/27/23 CMCSA

Technic Energies has withdrawn from Arctic LNG 2

7/27/23 NVTK

Bristol-Myers Squibb reported for 6 months of 2023

7/27/23 BMY

McDonald's reported for 6 months of 2023

7/27/23 MCD